Individuals bought KRW 230 billion, foreigners KRW 142.6 billion
In October, there was a clear difference in pharmaceutical stocks by investors.
According to the Korea Exchange, institutional investors’ net sales amounted to KRW 390.7 billion in October for 45 compositions of the pharmaceutical index.
Samsung Biologics was the only company that institutions net bought more than KRW 10 billion out of 45 stocks, but it did not exceed KRW 20 billion.
On the other hand, institutional investors net sold KRW 228.9 billion of Celltrion shares. Among the nearly 900 KOSPI stocks, Celltrion was the only one that exceeded KRW 200 billion in net selling by institutional investors in October.
They also net sold SK Bioscience for KRW 107.8 billion and GC Pharma for more than KRW 50 billion during the same period.
Individual and foreign investors bought a net KRW 230 billion and KRW 142.6 billion in a month.
In particular, individual investors absorbed most of the Celltrion shares sold by institutions. It recorded a net purchase of KRW 193.5 billion.
Net purchases of GC Pharma also exceeded KRW 50 billion by KRW 57.3 billion, and that of SK Bioscience reached KRW 43.6 billion. In addition, individual investors net bought Pharmicell and Dongwha Pharm over KRW 10 billion.
However, they sold a net KRW 59.2 billion of Samsung Biologics shares and KRW 21 billion of Shinpoong Pharmaceutical shares.
Foreign investors have expanded their horizons to various stocks.
They purchased a net KRW 64.9 billion of SK Bioscience, KRW 42.1 billion of Samsung Biologics, KRW 21.6 billion of Shinpoong Pharmaceutical, KRW 14.5 billion of Bukwang Pharmaceutical, KRW 12.1 billion of Celltrion, and KRW 11.6 billion of GeneOne Life Science.
Pharmicell was the sole company whose net selling by foreign investors exceeded KRW 10 billion.
